Advertisement

Drugs

, Volume 75, Issue 4, pp 439–443 | Cite as

Vonoprazan: First Global Approval

  • Karly P. Garnock-JonesEmail author
R&D Insight Report

Abstract

Vonoprazan (Takecab®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases. The drug is approved in Japan for the treatment of acid-related diseases, including erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication. Phase III development is underway for the prevention of recurrence of duodenal and gastric ulcer in patients receiving aspirin or NSAID therapy. Phase I development was conducted in the UK for gastro-oesophageal reflux; however, no further development has been reported. This article summarizes the milestones in the development of vonoprazan leading to this first approval for acid-related diseases.

Keywords

Peptic Ulcer Duodenal Ulcer Gastric Ulcer Pylorus Infection Clarithromycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this report was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. K. P. Garnock-Jones is a salaried employee of Adis, Springer SBM.

References

  1. 1.
    Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep. 2010;12(6):437–47.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Luo HJ, Deng WQ, Zou K. Protonated form: the potent form of potassium-competitive acid blockers. PLoS One. 2014;9(5):e97688.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412–20.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Takeda. New drug application approval of TAKECAB® for the treatment of acid-related diseases in Japan (media release). 26 Dec 2014. http://www.takeda.com.
  5. 5.
    Takeda. Takeda submits a new drug application for TAK-438 in Japan for the treatment of acid-related diseases (media release). 28 Feb 2014. http://www.takeda.co.jp.
  6. 6.
    Takeda. ClinicalTrials.gov. 2014. http://www.clinicaltrials.gov/. Accessed 30 Jan 2015.
  7. 7.
    Otsuka Pharmaceutical, Takeda Pharmaceutical Company Limited. Otsuka and Takeda announce a co-promotion agreement in Japan of TAK-438 for the treatment of acid-related diseases in the gastrointestinal therapeutic area (media release). 2014. http://www.otsuka.co.jp. Accessed 27 Mar 2014.
  8. 8.
    Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Takeda. Takecab® (vonoprazan tablets): Japanese prescribing information. 2014. http://www.takedamed.com/content/medicine/pdf/pre-takecab.pdf. Accessed 5 Feb 2015.
  10. 10.
    Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55(9):4446–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Mizokami Y, Ashida K, Soen S, et al. TAK-438 vs. lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a phase 3 trial [abstract no. Tu1054]. Gastroenterology. 2014;146(5 Suppl. 1):S-739.Google Scholar
  12. 12.
    Kawai T, Ashida K, Mizokami Y, et al. TAK-438 vs. lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a phase 3 trial (abstract no. Tu1055). Gastroenterology. 2014;146(5 Suppl. 1):S-739.Google Scholar
  13. 13.
    Iwakiri K, Umegaki E, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (20 mg once-daily) compared to lansoprazole (30 mg once-daily) in patients with erosive esophagitis (abstract no. Tu1059). Gastroenterology. 2014;146(5 Suppl. 1):S-741.Google Scholar
  14. 14.
    Umegaki E, Iwakiri K, Hiramatsu N, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to lansoprazole (15 mg once-daily) in a 24-week maintenance treatment for healed erosive esophagitis (abstract no. Tu1052). Gastroenterology. 2014;146(5 Suppl. 1):S-738.Google Scholar
  15. 15.
    Chiba T, Sakurai Y, Nishimura A, et al. A phase 2, randomized, double-blind, parallel-group, multicenter, dose-ranging study to evaluate the efficacy and safety of a novel potassium-competitive acid blocker (P-CAB) TAK-438 in patients with erosive esophagitis (abstract no. Mo1053). Gastroenterology. 2013;144(5 Suppl. 1):S-564-5.Google Scholar
  16. 16.
    Murakami K, Sakurai Y, Shiino M, et al. A newly developed potassium-competitive acid blocker, vonoprazan vs. Lansoprazole in first-line triple therapy with amoxicillin, and clarithromycin for H. pylori eradication—phase 3, double-blind study (abstract no. W2.2). Helicobacter. 2014;19(Suppl 1):79.Google Scholar
  17. 17.
    Murakami K, Sakurai Y, Shiino M, et al. A phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy With TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori (abstract no. Tu1056). Gastroenterology. 2014;146(5 Suppl. 1):S-740.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations